SOFOSBUVIR (SOF) 400mg / VELPATASVIR (VEL) 100mg, tab.


Valid Article

Former Code(s): DORASOVE4T- - Pangenotypic direct-acting antiviral combinations
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
Anatomical Therapeutic Chemical Classification according to WHOCC
The order of this product needs to be justified and is only acceptable under certain conditions.
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list


Add Kit To Wishlist



Therapeutic Action

Fixed-dose combination of a nucleotide analogue NS5B polymerase inhibitor (sofosbuvir) and an HCV NS5A inhibitor (velpatasvir)


Chronic Hepatitis C (CHC) infection

Some restricted information has been hidden. Sign in to see this information

Instructions for use

The dosage 200 mg / 50 mg is intended for paediatric use.

Precautions for Use

Contraindicated in pregnancy and breast-feeding.


Below 25°C